Teva Announces Tentative Approval Of Generic Prevacid® Delayed-Release Capsules

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted tentative approval for the Company’s Abbreviated New Drug Application (ANDA) to market its generic version of TAP Pharmaceutical’s gastric-acid pump inhibitor, Prevacid® (Lansoprazole) Delayed-release Capsules, 15 mg and 30 mg. The brand product had annual sales of approximately $3.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on January 29th, 2008